Compare ESI & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESI | PRAX |
|---|---|---|
| Founded | 1922 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.3B |
| IPO Year | 2014 | 2020 |
| Metric | ESI | PRAX |
|---|---|---|
| Price | $35.74 | $281.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $35.56 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 5.0M | 356.7K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $2,551,200,000.00 | N/A |
| Revenue This Year | $21.24 | N/A |
| Revenue Next Year | $7.34 | $7,758.26 |
| P/E Ratio | $150.00 | ★ N/A |
| Revenue Growth | ★ 3.84 | N/A |
| 52 Week Low | $22.86 | $50.23 |
| 52 Week High | $49.25 | $392.70 |
| Indicator | ESI | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 53.89 | 26.03 |
| Support Level | $33.80 | $269.44 |
| Resistance Level | $37.14 | $331.21 |
| Average True Range (ATR) | 1.13 | 15.24 |
| MACD | 0.36 | -5.85 |
| Stochastic Oscillator | 82.54 | 6.71 |
Element Solutions Inc is a specialty chemicals company whose businesses supply a broad range of solutions that enhance the performance of products people use every day. The company's reportable segments are Electronics and Industrial & Specialty. The Electronics segment, which generates maximum revenue, researches, formulates, and sells specialty chemicals and process technologies for all types of electronics hardware, from complex printed circuit board designs to semiconductor packaging. This segment's wet chemicals for metallization, surface treatments, and solderable finishes form the physical circuitry pathways, and its assembly materials, such as solder, pastes, fluxes, and adhesives, join those pathways together.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.